The estimated Net Worth of Cordell W Hull is at least $809 mil dollars as of 4 November 2003. Cordell Hull owns over 10,000 units of Gilead Sciences stock worth over $809,400 and over the last 21 years Cordell sold GILD stock worth over $0.
Cordell has made over 1 trades of the Gilead Sciences stock since 2003, according to the Form 4 filled with the SEC. Most recently Cordell exercised 10,000 units of GILD stock worth $196,200 on 4 November 2003.
The largest trade Cordell's ever made was exercising 10,000 units of Gilead Sciences stock on 4 November 2003 worth over $196,200. On average, Cordell trades about 10,000 units every 0 days since 2003. As of 4 November 2003 Cordell still owns at least 10,000 units of Gilead Sciences stock.
You can see the complete history of Cordell Hull stock trades at the bottom of the page.
Cordell's mailing address filed with the SEC is 400 OYSTER POINT BLVD., SUITE 410, SO. SAN FRANCISCO, CA, 94080.
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger y John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: